Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HK Stocks Tied to Minimally-invasive Medical Treatment Spike Broadly AM; MICROPORT NEURO Leaps ~21%
Recommend 7 Positive 7 Negative 0 |
||||
|
||||
|
HK-listed stocks related to theme of minimally-invasive medical treatment rallied across the board this morning (14th), with MICROPORT NEURO (02172.HK) posting the strongest gains. The stock opened 6.43% higher, peaking at HKD13.78, and last stood at HKD13.14, up 20.77%. Trading volume reached 17.617 million shares, with a turnover of HKD228 million. MICROPORT (00853.HK) opened 1.16% higher, hitting a high of HKD9.09. It last traded at HKD8.81, up 13.68%, with a volume of 36.8411 million shares and a turnover of HKD319 million. MEDBOT-B (02252.HK) opened 0.49% higher, reaching a high of HKD21.6. It last posted at HKD20.75, up 2.22%, with 4.31 million shares traded and a turnover of HKD90.1034 million. CARDIOFLOW-B (02160.HK) opened 1.82% lower, dipping to a low of HKD1.08. It has since recovered to HKD1.13, up 2.73%, with a trading volume of 1.965 million shares and a turnover of HKD2.2056 million. A recent JP Morgan report highlighted robust order trend of MEDBOT, noting its significance as a key subsidiary of MICROPORT. The broker expected the subsidiary’s contribution to group sales to rise from about 3% in 2024 to approximately 40% by 2033, on the ride of rapid robot installations in China and overseas markets. JP Morgan reiterated its positive outlook on MICROPORT, describing it as a diversified local leader in the small- and mid-cap (SMID) medtech sector, with strong innovation capabilities and overseas expansion potential. The broker projected a return to profitability by 2026 and continued to view MICROPORT as its top pick in the SMID medtech space. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
